Skip to main content
Contact Us
Subscribe
E-Edition
40°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ImmunoPrecise Antibodies Ltd. - Common Stock
(NQ:
IPA
)
0.4218
-0.0222 (-5.00%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ImmunoPrecise Antibodies Ltd. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture
January 27, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
What's Going On With ImmunoPrecise Antibodies Stock Wednesday?
January 22, 2025
Immunoprecise shares closed higher on Wednesday after the company announced it developed a new class of GLP-1 therapies.
Via
Benzinga
Trump’s “Stargate AI” Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO
January 22, 2025
Via
AB Newswire
Topics
Artificial Intelligence
Government
Exposures
Artificial Intelligence
Political
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
January 22, 2025
Via
Benzinga
Exposures
Fossil Fuels
ImmunoPrecise Antibodies: Q2 Earnings Insights
December 10, 2024
Via
Benzinga
A Preview Of ImmunoPrecise Antibodies's Earnings
December 09, 2024
Via
Benzinga
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings
January 22, 2025
Via
Benzinga
US Stocks Higher; Netflix Profit Beats Estimates
January 22, 2025
Via
Benzinga
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
January 22, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
January 22, 2025
Via
Benzinga
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
January 17, 2025
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Announces Resignation of Chief Financial Officer
December 31, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases
December 23, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Present at The Microcap Conference 2025
December 19, 2024
Via
ACCESSWIRE
IPA to Present at The Microcap Conference 2025
December 19, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
December 10, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Earnings Scheduled For December 10, 2024
December 10, 2024
Via
Benzinga
IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
December 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024
December 03, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
November 13, 2024
Via
AB Newswire
Topics
Electric Vehicles
Exposures
Electric Vehicles
Product Safety
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
November 13, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
November 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
October 28, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
October 21, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
October 10, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
October 02, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
September 26, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
September 16, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
September 09, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 26, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
